This is healthcare disruption. And it’s happening.
We believe cannabis is in the nascent stages of a multi-year efficacy-led bull market and will separate into several categories – consumer packaged goods, including beverages and nutraceuticals, industrial use-cases, such as plastic composites and hempcrete, and efficacy-driven solutions, or biotech.
We believe the collective perception will shift from viewing cannabis as a discretionary vice to one with an abundance of use-cases.
CB1 Capital does not touch the plant or move the plant across state lines; we buy, sell, and invest in securities of publicly traded companies and select private ventures, and advise emerging companies in the space.